• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    NewAmsterdam Pharma Company N.V. - Warrant (NQ:NAMSW)

    29.70 -0.27 (-0.90%)
    Streaming Delayed Price Updated: 10:09 AM EST, Nov 28, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,000
    Open 29.73
    Bid (Size) 7.490 (100)
    Ask (Size) 32.90 (100)
    Prev. Close 29.97
    Today's Range 29.70 - 29.73
    52wk Range 5.450 - 29.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire

    Performance

    YTD
    +106.4%
    +106.4%
    1 Month
    +8.8%
    +8.8%
    3 Month
    +121.6%
    +121.6%
    6 Month
    +228.5%
    +228.5%
    1 Year
    +227.8%
    +227.8%

    More News

    Read More
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Host R&D Day on June 11, 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire
    News headline image
    NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
    From NewAmsterdam Pharma N.V.
    Via GlobeNewswire

    Frequently Asked Questions

    Is NewAmsterdam Pharma Company N.V. - Warrant publicly traded?
    Yes, NewAmsterdam Pharma Company N.V. - Warrant is publicly traded.
    What exchange does NewAmsterdam Pharma Company N.V. - Warrant trade on?
    NewAmsterdam Pharma Company N.V. - Warrant trades on the Nasdaq Stock Market
    What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Warrant?
    The ticker symbol for NewAmsterdam Pharma Company N.V. - Warrant is NAMSW on the Nasdaq Stock Market
    What is the current price of NewAmsterdam Pharma Company N.V. - Warrant?
    The current price of NewAmsterdam Pharma Company N.V. - Warrant is 29.70
    When was NewAmsterdam Pharma Company N.V. - Warrant last traded?
    The last trade of NewAmsterdam Pharma Company N.V. - Warrant was at 11/28/25 10:09 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.